Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality-Reference-Cited by-同舟云学术

Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality

Published:2022-08 Issue:8 Volume:28 Page:510.e1-510.e9
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Liu Lawrence Wayne^ORCID,Yn Alicia,Gao Feng^ORCID,Olson Marissa^ORCID,Crain Mallory^ORCID,Abboud Ramzi^ORCID,Westervelt Peter,Abboud Camille^ORCID,Vij Ravi,Stockerl-Goldstein Keith^ORCID,Pusic Iskra,Cashen Amanda F.,Schroeder Mark A.

Publisher

Elsevier BV

Subject

Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy

Reference32 articles.

1. Cytomegalovirus infection in the bone marrow transplant patient;Bhat;World J Transplant,2015

2. Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies;Boeckh;Biol Blood Marrow Transplant,2003

3. The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplantation: why the quest for meaningful prophylaxis still matters;Chan;Blood Rev,2017

4. Clinical aspects and management of cytomegalovirus infection;Sissons;J Infect,2002

5. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation;Marty;N Engl J Med,2017

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world experience with letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation: A multi-centre observational study;Journal of Infection;2024-08

2. Late cytomegalovirus disease after hematopoietic cell transplantation: significance of novel transplantation techniques;Blood Advances;2024-07-11

3. Refractory/Resistant Cytomegalovirus Infection in Transplant Recipients: An Update;Viruses;2024-07-05

4. Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment;Nature Communications;2024-04-18

5. Advances in pharmacotherapies for cytomegalovirus infection: what is the current state of play?;Expert Opinion on Pharmacotherapy;2024-04-12